SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences informs about press release

17 Feb 2023 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated February 17, 2023 titled ‘Zydus receives final approval from the USFDA for Sirolimus Tablets, 1 mg and 2 mg’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

947.10 17.50 (1.88%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×